Skip to main content

Table 2 Demographics of ODMT patients

From: Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review

 

Total

FTY

DMF

TFN

P-value (3 groups)

(N = 293)

(N = 101)

(N = 133)

(N = 59)

Female, n (%)

214 (73.0)

75 (74.3)

96 (72.2)

43 (72.9)

0.9386

Mean age, y (SD)

48.0 (10.7)

44.2 (10.7)

49.6 (10.3)

50.6 (9.6)

<0.0001

Age group, n (%)

    

0.0349

 18–24 years

2 (0.7)

2 (2.0)

0

0

 

 25–34 years

33 (11.3)

18 (17.8)

12 (9.1)

3 (5.1)

 

 35–44 years

81 (27.7)

34 (33.7)

32 (24.2)

15 (25.4)

 

 45–54 years

100 (34.3)

31 (30.7)

49 (37.1)

20 (33.9)

 

 55–64 years

59 (20.2)

12 (11.9)

29 (22.0)

18 (30.5)

 

 65–74 years

13 (4.5)

4 (4.0)

7 (5.3)

2 (3.4)

 

 75+ years

4 (1.4)

0

3 (2.3)

1 (1.7)

 

 Missing

1 (0.3)

0

0

0

 

Region, n (%)

    

<0.0001

 Midwest

73 (25.1)

32 (32.3)

37 (27.8)

4 (6.8)

 

 Northeast

58 (19.9)

24 (24.2)

26 (19.6)

8 (13.6)

 

 South

105 (36.1)

42 (42.4)

37 (27.8)

26 (44.1)

 

 West

55 (18.9)

1 (1.0)

33 (24.8)

21 (35.6)

 

 Missing

2 (0.7)

0

0

0

 

Race, n (%)

    

0.0074

 White

61 (21.1)

29 (28.7)

28 (21.5)

4 (6.9)

 

 Black

11 (3.8)

7 (6.9)

1 (0.8)

3 (5.2)

 

 Other

3 (1.0)

1 (1.0)

1 (0.8)

1 (1.7)

 

 Unknown

214 (74.1)

64 (63.4)

100 (76.9)

50 (86.2)

 

 Missing

4 (1.4)

0

0

0

 

Insurance, n (%)

    

0.0051

 Commercial

70 (24.1)

15 (15.0)

35 (26.5)

20 (34.5)

 

 Medicaid

8 (2.8)

0

6 (4.6)

2 (3.5)

 

 Medicare

28 (9.7)

4 (4.0)

16 (12.1)

8 (13.8)

 

 Cash

2 (0.7)

1 (1.0)

1 (0.8)

0

 

 Other

5 (1.7)

2 (2.0)

3 (2.3)

0

 

 Unknown

177 (61.0)

78 (78.0)

71 (53.8)

28 (48.3)

 

 Missing

3 (1.0)

0

0

0

 
  1. DMF dimethyl fumarate, ODMT oral disease-modifying therapy, FTY fingolimod, TFN teriflunomide